financetom
Business
financetom
/
Business
/
Housing Stocks Are On The Rise Today: What's Going On?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Housing Stocks Are On The Rise Today: What's Going On?
Jan 27, 2025 2:06 PM

Shares of housing stocks including NVR Inc. ( NVR ) and D.R. Horton Inc. ( DHI ) traded higher on Monday, likely driven by a better-than-expected report on U.S. new home sales for December.

What To Know: According to Reuters, the U.S. Commerce Department reported new home sales increased 3.6% to a seasonally adjusted annual rate of 698,000 units in December, exceeding economists’ expectations of 675,000 units. This marked a 6.7% year-over-year increase and contributed to a total of 683,000 new homes sold in 2024, a 2.5% gain from 2023. The median new home price rose 2.1% from the prior year to $427,000, although rising inventory appears to be tempering price growth.

This data potentially indicates sustained momentum in the housing market despite high mortgage rates, which have constrained activity overall. Builders are responding by constructing smaller, more affordable homes to attract buyers, while the inventory of new homes reached 494,000 units in December—the highest level since 2007. Notably, 118,000 homes were completed, the most since 2009.

Both companies operate as real estate investment trusts (REITs) focused on essential infrastructure, such as cell towers, which benefit indirectly from increased housing development and connectivity demands in growing residential areas. Rising demand for new housing may also spur further investments in telecommunications infrastructure, fueling optimism among investors about these stocks’ long-term growth potential.

Price Action: NVR shares closed up 2.22% at $8,382.63 and D.R. Horton ( DHI ) shares closed up 3.05% at $147.26 at the time of publication Monday, according to Benzinga Pro.

Read Next:

Newmont Completes $425 Million Asset Sale, Focuses On British Columbia Growth

Image Via Shutterstock.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Top Premarket Gainers
Top Premarket Gainers
Jul 24, 2024
07:37 AM EDT, 07/24/2024 (MT Newswires) -- Dermata Therapeutics ( DRMA ) shares more than doubled, reversing Tuesday's slump. Pieris Pharmaceuticals ( PIRS ) shares surged 78% after the company agreed to merge with Palvella Therapeutics in an all-stock deal. Regencell Bioscience ( RGC ) shares advanced 40%, extending Tuesday's rally. Perfect Moment ( PMNT ) shares were up 7%,...
Tilray Medical Granted Approval to Introduce Third Medical Cannabis Product in Portugal
Tilray Medical Granted Approval to Introduce Third Medical Cannabis Product in Portugal
Jul 24, 2024
07:40 AM EDT, 07/24/2024 (MT Newswires) -- Cannabis company Tilray Brands ( TLRY ) announced Wednesday that subsidiary Tilray Medical has received official approval for a new medical cannabis extract in Portugal. This follows the approval of Tilray Medical whole flower THC 18, and for the first cannabis extract in Portugal earlier this year. This is a significant step towards...
IDB and Brazil's public banks to launch Amazon ETF, say sources
IDB and Brazil's public banks to launch Amazon ETF, say sources
Jul 24, 2024
RIO DE JANEIRO, July 24 (Reuters) - The Inter-American Development Bank (IDB) and Brazil's public banks will announce on Thursday the development of an exchange-traded fund (ETF) focused on sustainable investments in the Amazon rainforest, said two people with direct knowledge. State development bank BNDES, Banco do Brasil and Caixa Economica Federal are part of the initiative, said the sources,...
Pfizer Says Phase 3 Study of Potential Gene Therapy in Hemophilia Meets Goals
Pfizer Says Phase 3 Study of Potential Gene Therapy in Hemophilia Meets Goals
Jul 24, 2024
07:39 AM EDT, 07/24/2024 (MT Newswires) -- Pfizer ( PFE ) said Wednesday its phase 3 study evaluating its investigational gene therapy giroctocogene fitelparvovec in adults with moderately severe to severe hemophilia met its primary and secondary goals of superiority compared with prophylaxis. After a single dose, participants posted a statistically significant reduction in mean annualized bleeding rates compared to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved